SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Biocept, Inc.
(Nasdaq: BIOC), a leading commercial provider of molecular
diagnostic tests and services for physicians treating patients with
cancer, announces an update on its COVID-19 testing with more than
100,000 samples received to date for processing through its RT-PCR
technology at its CLIA-certified, CAP-accredited high-complexity
molecular laboratory.
"We are providing COVID-19 testing to a growing list of clients
including skilled nursing centers, hospitals, clinics and surgery
centers. The majority of our customers are located in
California, but we are receiving
samples from across the country," said Michael Nall, President and CEO of
Biocept. "We are committed to providing this important
service during the pandemic and we continue to return the vast
majority of COVID-19 test results to our customers within 48 hours
of receiving a sample.
"We expect COVID-19 RT-PCR testing will have a significant
positive impact on our revenues through the remainder of the year
and continuing into 2021," he added.
About Biocept
Biocept, Inc. is a molecular diagnostics
company with commercialized assays for lung, breast, gastric,
colorectal and prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options.
Additionally, Biocept is offering nationwide COVID-19
polymerase chain reaction (PCR) testing to support public health
efforts during this unprecedented pandemic. For more
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. To the extent that statements in this
release are not strictly historical, including without limitation
statements regarding our expectation that COVID-19 RT-PCR testing
will have a significant positive impact on our revenues through the
remainder of the year and continuing into 2021, and the ability of
Biocept's platform to identify cancer mutations and alterations to
inform physicians about a patient's disease and therapeutic
options, such statements are forward-looking, and are made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our Securities
and Exchange Commission (SEC) filings. The effects of such risks
and uncertainties could cause actual results to differ materially
from the forward-looking statements contained in this release. We
do not plan to update any such forward-looking statements and
expressly disclaim any duty to update the information contained in
this press release except as required by law. Readers are advised
to review our filings with the SEC, which can be accessed over the
Internet at the SEC's website located at www.sec.gov.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-provides-update-on-covid-19-testing-with-more-than-100-000-samples-received-301171466.html
SOURCE Biocept, Inc.